John W. Smither

Board Director

Director

eFFECTOR Therapeutics, Inc.Genelux Corp Arcutis Biotherapeutics, Inc.NewAmsterdam Pharma Co N.V.MBX Biosciences, Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 1 saleOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

—

▼ Sales (2 ops.)

€52k

Latest filing published 09 Sept 2026 for NewAmsterdam Pharma Co N.V., €35k. Read the official filing

Filing timeline

BuySale

John W. Smither

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

No signal scores available.

John W. Smither: trading record in brief

John W. Smither is a declared insider at 5 companies (board member); the most frequent names are Genelux Corp, NewAmsterdam Pharma Co N.V. and Arcutis Biotherapeutics, Inc. Over a trading history stretching from 25 August 2021 to 4 September 2026, the count stands at 12 filings.

Market trades split into 1 purchase and 2 sales (€52k). The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 9 share grants. 2026 to date brings no purchases and 1 sale.

The latest filing, published on 9 September 2026, reports an open-market sale of €35k in NewAmsterdam Pharma Co N.V. The latest purchase dates back some time: it was published 863 days ago, on 7 June 2024. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.